Pharmaceuticals Europe

Europe Diabetes Drugs Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe Diabetes Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $13.93 Bn Placeholder estimate
Estimate 2025 $14.76 Bn 19% of the global market
Projected 2034 $24.72 Bn 67.5% Adds $9.96 Bn over 9 forecast years
CAGR 2025–2034 5.9% Faster than 43% of 183 Pharmaceuticals markets here
Key players 6 +1
  • Europe is 18.95% of the global market.
  • Among regions, the largest is North America at $40.19 Bn.
  • Fastest growing: Africa at 8.9% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$9.96 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Diabetes Drugs Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $13.93 Bn — —
2025 (base) $14.76 Bn +$822.1 Mn —
2026 (forecast) $15.63 Bn +$870.7 Mn +5.9%
2027 (forecast) $16.55 Bn +$922.0 Mn +12.1%
2028 (forecast) $17.53 Bn +$976.4 Mn +18.8%
2029 (forecast) $18.56 Bn +$1.03 Bn +25.8%
2030 (forecast) $19.66 Bn +$1.10 Bn +33.2%
2031 (forecast) $20.81 Bn +$1.16 Bn +41.1%
2032 (forecast) $22.04 Bn +$1.23 Bn +49.4%
2033 (forecast) $23.34 Bn +$1.30 Bn +58.2%
2034 (forecast) $24.72 Bn +$1.38 Bn +67.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Diabetes Drugs Market Analysis at a glance
Market size, 2025$14.76 Bn placeholder estimate
Forecast, 2034$24.72 Bn placeholder estimate
Growth (CAGR), 2025–20345.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and 1 more (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials909 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 21 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Diabetes Drugs Market Analysis Executive Summary

Diabetes drugs lower blood sugar in people with type 1 or type 2 diabetes, including insulin, pills and injectable GLP-1 medicines.

Key segments of the diabetes drugs market include drug class (Insulin, GLP-1 Agonists and SGLT2 Inhibitors) and route (Oral and Injectable).

Bar chart: Europe Diabetes Drugs market size, 2024–2034, placeholder estimates. $13.93 Bn in 2024, $14.76 Bn in 2025 and $24.72 Bn in 2034, 5.9% CAGR.
Europe Diabetes Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Diabetes Drugs Market Dynamics

Market Growth Drivers

Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.

Opportunity

Connected devices, lower-priced sensors and new insulins and pills give the diabetes drugs market room to grow.

Market Restraints

High costs for people without cover, price competition and uneven access to care in low-income countries hold back the diabetes drugs market.

Competitive Landscape for Diabetes Drugs Market in Europe

The diabetes drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Diabetes Drugs Market in Europe

Diabetes Drugs in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], CBG-MEB (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 909 studies on Diabetes Drugs that are recruiting, active or about to start in Europe.⁠[16]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 21 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for diabetes drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Diabetes Drugs right now, from free public sources.

Clinical trials

909 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia

Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.

See every trial on ClinicalTrials.gov (opens in a new tab)

Patients

Diabetes (ages 20–79), % of people 20–79 (World Bank)
CountryValueYear
Belgium5.92024
Denmark6.42024
France6.52024
Germany7.82024
Italy7.72024
Netherlands5.02024
Poland8.12024
Russia5.92024
Spain9.72024
Sweden5.82024
Switzerland5.32024
Turkey16.52024
UK7.42024
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Diabetes Drugs in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Diabetes Drugs market in Europe?
Placeholder estimate: about $14.76 Bn in 2025, rising to about $24.72 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Diabetes Drugs market in Europe growing?
Placeholder estimate: about 5.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Diabetes Drugs market report cover?
The report splits the market by drug class (Insulin, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors and more), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Diabetes Drugs market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, AstraZeneca, Merck & Co., Inc. and Boehringer Ingelheim GmbH.
What is driving the Diabetes Drugs market?
Rising numbers of people with diabetes, a shift to tools that track and deliver treatment automatically, and more insurance cover are driving the diabetes drugs market.
Who regulates Diabetes Drugs in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Diabetes Drugs are running in Europe?
909 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 21 Nov 2026.
How much research is published on Diabetes Drugs?
PubMed lists 213 papers on Diabetes Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 21 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on diabetes

See the topic